{"id":"apixaban-2-5-milligram","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Bleeding (major and minor)"},{"rate":"0.5-1","effect":"Gastrointestinal bleeding"},{"rate":"1-2","effect":"Nausea"},{"rate":"0.5-1","effect":"Syncope"}]},"_chembl":{"chemblId":"CHEMBL231779","moleculeType":"Small molecule","molecularWeight":"459.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Apixaban selectively inhibits Factor Xa, a serine protease critical in both the intrinsic and extrinsic coagulation pathways. By blocking Factor Xa activity, it prevents the generation of thrombin and subsequent fibrin clot formation, thereby reducing thrombotic events. This direct mechanism allows for predictable anticoagulation without requiring monitoring.","oneSentence":"Apixaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:29.820Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Deep vein thrombosis (DVT) treatment and prevention"},{"name":"Pulmonary embolism (PE) treatment and prevention"},{"name":"Thromboprophylaxis after hip or knee replacement surgery"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["medication adherence assessment"],"phase":"marketed","status":"active","brandName":"Apixaban 2.5 milligram","genericName":"Apixaban 2.5 milligram","companyName":"McMaster University","companyId":"mcmaster-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Apixaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis (DVT) treatment and prevention, Pulmonary embolism (PE) treatment and prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}